Lactobacillus gasseri 用于 幽门螺杆菌感染
B 证据 至少一项随机试验支持这一结论，结果基本一致。三项RCT显示，与标准三联疗法联合使用时，加氏乳杆菌LG21可抑制幽门螺杆菌载量并提高根除率。同时改善GERD症状。
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dgasseri\u0026condition\u003Dh\u002Dpylori';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
结论
三项RCT显示，与标准三联疗法联合使用时，加氏乳杆菌LG21可抑制幽门螺杆菌载量并提高根除率。同时改善GERD症状。
Key Study Findings
In Vitro
Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in …
Dose: None
vs: H. pylori infection without lactobacilli
Outcome: ADAM17, HBEGF, TGF-alpha expression
效果: None
None
研究人群: AGS gastric epithelial cells and mouse model
In Vitro
Lactobacillus gasseri Suppresses the Helicobacter pylori-Induced Hummingbird Phenotype by Inhibiting CagA Phosphorylation and SHP-2 Interaction.
Dose: None
vs: CagA-expressing AGS cells without L. gasseri
Outcome: Suppression of CagA phosphorylation (hummingbird)
效果: None
None
研究人群: Human gastric AGS cell line with H. pylori CagA
In Vitro
The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of …
Dose: 50 μg/ml
vs: None
Outcome: Inflammatory markers
效果: None
None
研究人群: None
Other
Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter …
Dose: None
vs: None
Outcome: Inflammatory markers
效果: None
None
研究人群: Cancer patients
Other
Two novel lactic acid bacteria, Limosilactobacillus fermentum MN-LF23 and Lactobacillus gasseri MN-LG80, inhibited Helicobacter pylori …
Dose: None
vs: None
Outcome: H. pylori abundance reduction
效果: None
None
研究人群: H. pylori-infected C57BL/6 mice
Case-Control
n=178
Oral and gastric microbiome in relation to gastric intestinal metaplasia.
Dose: None
vs: None
Outcome: Oral/gastric microbiome associations with IM
效果: None
None
研究人群: Gastric intestinal metaplasia cases and matched controls
Key Statistics
3
研究数量
350
受试者
↑
Positive
B
等级
Referenced Papers
International journal of …
2025
4 次引用
International journal of …
2025
Microbial pathogenesis
2024
8 次引用
Helicobacter
2024
5 次引用
International journal of …
2022
59 次引用
BMC microbiology
2022
28 次引用
Food & function
2022
19 次引用
Probiotics and antimicrobial …
2021
30 次引用
Comparative immunology, microbiology …
2019
72 次引用
Frontiers in immunology
2019
61 次引用
Frontiers in microbiology
2019
31 次引用
BMJ open gastroenterology
2019
14 次引用
Digestion
2017
67 次引用
Gastroenterology research and …
2016
38 次引用
Helicobacter
2015
26 次引用
PloS one
2014
171 次引用
Frontiers in microbiology
2014
78 次引用
Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health.
Review
FEMS microbiology reviews
2013
196 次引用
Journal of gastroenterology …
2012
76 次引用
Journal of food …
2012
56 次引用
Journal of clinical …
2012
37 次引用
Journal of dairy …
2010
43 次引用
Journal of medicinal …
2010
19 次引用
Probiotics and antimicrobial …
2010
9 次引用
Helicobacter
2009
48 次引用
Cellular microbiology
2006
50 次引用
Journal of gastroenterology …
2006
41 次引用
Letters in applied …
2006
26 次引用
Journal of pharmacological …
2004
58 次引用
Journal of gastroenterology …
2003
77 次引用
Effects of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in children.
Other
The Journal of …
2002
31 次引用
The Journal of …
2001
309 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 1-10 billion CFU/day
- gerdsupport:
- 1-5 billion CFU/day
- hpylorisupport:
- 100 million CFU/day (LG21 strain, yogurt form) for 8-12 weeks
上限： Well-tolerated up to 10 billion CFU/day in clinical trials
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| 50 μg/ml | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Neutral | 178 |
| None | -- | Positive | -- |
| 1 g | -- | Positive | -- |
最佳服用时间： Before meals or with meals; yogurt form taken with food
Safety & Side Effects
已报告的副作用
- ⚠ Mild gas during initial use
- ⚠ Occasional loose stools
- ⚠ Rare abdominal discomfort
- ⚠ Very rare: bacteremia in immunocompromised individuals
已知相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Proton pump inhibitors (altered gastric pH may affect colonization)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
可耐受最高摄入量： Well-tolerated up to 10 billion CFU/day in clinical trials
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Lactobacillus gasseri help with 幽门螺杆菌感染?
Based on 3 studies with 350 participants, there is moderate evidence from clinical studies that Lactobacillus gasseri may support 幽门螺杆菌感染 management. Our evidence grade is B (Good Evidence).
How much Lactobacillus gasseri should I take for 幽门螺杆菌感染?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus gasseri?
Reported side effects may include Mild gas during initial use, Occasional loose stools, Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus gasseri and 幽门螺杆菌感染?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 350 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 幽门螺杆菌感染
Lactobacillus gasseri 用于其他健康状况
References
- [1] Rajesh K Gupta et al.. Int J Mol Sci. 2025. Lactobacillus gasseri Suppresses the Helicobacter pylori-Induced Hummingbird Phenotype by Inhibiting CagA Phosphorylation and SHP-2 Interaction. doi:10.3390/ijms26146718 PubMed
- [2] Tanvi Somiah et al.. Int J Med Microbiol. 2025. Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in gastric host cells. doi:10.1016/j.ijmm.2025.151694 PubMed
- [3] Zahra Sadeghloo et al.. Microb Pathog. 2024. The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of Helicobacter pylori in gastric epithelial … doi:10.1016/j.micpath.2024.106559 PubMed
- [4] Marine Jauvain et al.. Helicobacter. 2024. Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter pylori Infection. doi:10.1111/hel.13108 PubMed
- [5] Fen Wu et al.. Int J Cancer. 2022. Oral and gastric microbiome in relation to gastric intestinal metaplasia. doi:10.1002/ijc.33848 PubMed
- [6] Tran Thi Dieu Thuy et al.. BMC Microbiol. 2022. Anti-Helicobacter pylori activity of potential probiotic Lactiplantibacillus pentosus SLC13. doi:10.1186/s12866-022-02701-z PubMed
- [7] Yuyang Zhao et al.. Food Funct. 2022. Two novel lactic acid bacteria, Limosilactobacillus fermentum MN-LF23 and Lactobacillus gasseri MN-LG80, inhibited Helicobacter pylori infection in C57BL/6 mice. doi:10.1039/d2fo02034c PubMed
- [8] Mahdieh Yarmohammadi et al.. Probiotics Antimicrob Proteins. 2021. Effects of a Potential Probiotic Strain Lactobacillus gasseri ATCC 33323 on Helicobacter pylori-Induced Inflammatory Response and Gene Expression in Coinfected … doi:10.1007/s12602-020-09721-z PubMed
- [9] Majid Eslami et al.. Comp Immunol Microbiol Infect Dis. 2019. Are probiotics useful for therapy of Helicobacter pylori diseases? doi:10.1016/j.cimid.2019.02.010 PubMed
- [10] Hanna G Gebremariam et al.. Front Immunol. 2019. Lactobacillus gasseri Suppresses the Production of Proinflammatory Cytokines in Helicobacter pylori-Infected Macrophages by Inhibiting the Expression of ADAM17. doi:10.3389/fimmu.2019.02326 PubMed
- [11] Fanglei Zuo et al.. Front Microbiol. 2019. Role of Sortase A in Lactobacillus gasseri Kx110A1 Adhesion to Gastric Epithelial Cells and Competitive Exclusion of Helicobacter pylori. doi:10.3389/fmicb.2019.02770 PubMed
- [12] Yasuhiro Koga et al.. BMJ Open Gastroenterol. 2019. Probiotic L. gasseri strain (LG21) for the upper gastrointestinal tract acting through improvement of indigenous microbiota. doi:10.1136/bmjgast-2019-000314 PubMed
- [13] Toshihiro Ohtsu et al.. Digestion. 2017. The Ameliorating Effect of Lactobacillus gasseri OLL2716 on Functional Dyspepsia in Helicobacter pylori-Uninfected Individuals: A Randomized Controlled Study. doi:10.1159/000479000 PubMed
- [14] Atsushi Takagi et al.. Gastroenterol Res Pract. 2016. Effects of Lactobacillus gasseri OLL2716 on Helicobacter pylori-Associated Dyspepsia: A Multicenter Randomized Double-Blind Controlled Trial. doi:10.1155/2016/7490452 PubMed
- [15] Hidenori Matsui et al.. Helicobacter. 2015. Mouse Models for Assessing the Protective Efficacy of Lactobacillus gasseri SBT2055 against Helicobacter suis Infection Associated with the Development of … doi:10.1111/hel.12203 PubMed
- [16] Yini Dang et al.. PLoS One. 2014. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. doi:10.1371/journal.pone.0111030 PubMed
- [17] Susana Delgado et al.. Front Microbiol. 2014. Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric … doi:10.3389/fmicb.2014.00766 PubMed
- [18] Kurt Selle et al.. FEMS Microbiol Rev. 2013. Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health. doi:10.1111/1574-6976.12021 PubMed
- [19] Ryuzo Deguchi et al.. J Gastroenterol Hepatol. 2012. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. doi:10.1111/j.1440-1746.2011.06985.x PubMed
- [20] Xiaohua Chen et al.. J Food Sci. 2012. Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells. doi:10.1111/j.1750-3841.2011.02498.x PubMed
- [21] Shigeru Fujimura et al.. J Clin Microbiol. 2012. Probiotic mechanism of Lactobacillus gasseri OLL2716 strain against Helicobacter pylori. doi:10.1128/JCM.06262-11 PubMed
- [22] X Chen et al.. J Dairy Sci. 2010. In vitro screening of lactobacilli with antagonistic activity against Helicobacter pylori from traditionally fermented foods. doi:10.3168/jds.2010-3449 PubMed
- [23] Yuko Kato-Mori et al.. J Med Food. 2010. Fermentation metabolites from Lactobacillus gasseri and Propionibacterium freudenreichii exert bacteriocidal effects in mice. doi:10.1089/jmf.2010.1137 PubMed
- [24] Luc De Vuyst et al.. Probiotics Antimicrob Proteins. 2010. Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori. doi:10.1007/s12602-009-9029-4 PubMed
- [25] Surasak Boonyaritichaikij et al.. Helicobacter. 2009. Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection. doi:10.1111/j.1523-5378.2009.00675.x PubMed
- [26] Takeshi Shimosato et al.. Cell Microbiol. 2006. Strong immunostimulatory activity of AT-oligodeoxynucleotide requires a six-base loop with a self-stabilized 5'-C...G-3' stem structure. doi:10.1111/j.1462-5822.2005.00640.x PubMed
- [27] Akira Tamura et al.. J Gastroenterol Hepatol. 2006. Suppression of Helicobacter pylori-induced interleukin-8 production in vitro and within the gastric mucosa by a live Lactobacillus strain. doi:10.1111/j.1440-1746.2006.04318.x PubMed
- [28] S Fujimura et al.. Lett Appl Microbiol. 2006. Detection of Lactobacillus gasseri OLL2716 strain administered with yogurt drink in gastric mucus layer in humans. doi:10.1111/j.1472-765X.2006.02017.x PubMed
- [29] Masayuki Uchida et al.. J Pharmacol Sci. 2004. Yogurt containing Lactobacillus gasseri OLL2716 exerts gastroprotective action against [correction of agaisnt] acute gastric lesion and antral ulcer in rats. doi:10.1254/jphs.fpj04027x PubMed
- [30] Atsushi Ushiyama et al.. J Gastroenterol Hepatol. 2003. Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection. doi:10.1046/j.1440-1746.2003.03102.x PubMed
- [31] Toshiaki Shimizu et al.. J Antimicrob Chemother. 2002. Effects of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in children. doi:10.1093/jac/dkf157 PubMed
- [32] I Sakamoto et al.. J Antimicrob Chemother. 2001. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. doi:10.1093/jac/47.5.709 PubMed
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。